In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
Sreeranganathan M, Uthaman S, Sarmento B, et al. Int J Nanomedicine. 2017;12:7165–7182.
When reviewing the paper, the authors noted some errors in Figure 2E (page 7171) and Figure 6 (page 7176). They confirm that the corrections to Figures 2 and 6 do not alter the inferences or conclusion of the respective figures, nor the overall conclusion of the article, and apologize for this inadvertent error.
In the original manuscript, Figure 2 represents the cellular internalization of the nanoparticles and Figure 2E represents the uptake of targeted nanoparticles by MKN-28 cells at a higher magnification. In Figure 2E, the fluorescence image was wrongly merged with the incorrect brightfield image of the cell. The authors have rectified this mistake by replacing Figure 2E with the confocal microscope image using the correct phase contrast, fluorescent, and merged images. The corrected version of Figure 2 is included as follows.
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]